+

PL3034073T3 - Zastosowanie kompozycji zawierającej formoterol i dipropionian beklometazonu do zapobiegania i/lub leczenia zaostrzenia astmy - Google Patents

Zastosowanie kompozycji zawierającej formoterol i dipropionian beklometazonu do zapobiegania i/lub leczenia zaostrzenia astmy

Info

Publication number
PL3034073T3
PL3034073T3 PL16152451T PL16152451T PL3034073T3 PL 3034073 T3 PL3034073 T3 PL 3034073T3 PL 16152451 T PL16152451 T PL 16152451T PL 16152451 T PL16152451 T PL 16152451T PL 3034073 T3 PL3034073 T3 PL 3034073T3
Authority
PL
Poland
Prior art keywords
formoterol
exacerbation
asthma
prevention
treatment
Prior art date
Application number
PL16152451T
Other languages
English (en)
Inventor
Paolo Chiesi
Ivano Rondelli
Daniela Acerbi
Gianluigi Poli
Original Assignee
Chiesi Farm Spa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=38458097&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=PL3034073(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Chiesi Farm Spa filed Critical Chiesi Farm Spa
Publication of PL3034073T3 publication Critical patent/PL3034073T3/pl

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/16Amides, e.g. hydroxamic acids
    • A61K31/165Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A61K31/167Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the nitrogen of a carboxamide group directly attached to the aromatic ring, e.g. lidocaine, paracetamol
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/56Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/007Pulmonary tract; Aromatherapy
    • A61K9/0073Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A61K9/0075Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy for inhalation via a dry powder inhaler [DPI], e.g. comprising micronized drug mixed with lactose carrier particles
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/007Pulmonary tract; Aromatherapy
    • A61K9/0073Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A61K9/008Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy comprising drug dissolved or suspended in liquid propellant for inhalation via a pressurized metered dose inhaler [MDI]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/14Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605Excipients; Inactive ingredients
    • A61K9/1617Organic compounds, e.g. phospholipids, fats
    • A61K9/1623Sugars or sugar alcohols, e.g. lactose; Derivatives thereof; Homeopathic globules
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • A61P11/06Antiasthmatics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Pulmonology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pain & Pain Management (AREA)
  • Otolaryngology (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
PL16152451T 2007-04-19 2008-04-16 Zastosowanie kompozycji zawierającej formoterol i dipropionian beklometazonu do zapobiegania i/lub leczenia zaostrzenia astmy PL3034073T3 (pl)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
EP07007930A EP1982709A1 (en) 2007-04-19 2007-04-19 Use of a composition comprising formoterol and beclomethasone dipropionate for the prevention or treatment of an acute condition of asthma
EP08748930.8A EP2146704B1 (en) 2007-04-19 2008-04-16 Use of a composition comprising formoterol and beclometasone dipropionate for the treatment of an exacerbation of asthma
PCT/EP2008/003012 WO2008128685A1 (en) 2007-04-19 2008-04-16 Use of a composition comprising formoterol and beclometasone dipropionate for the prevention and/or treatment of an exacerbation of asthma
EP16152451.7A EP3034073B1 (en) 2007-04-19 2008-04-16 Use of a composition comprising formoterol and beclometasone dipropionate for the prevention and/or treatment of an exacerbation of asthma

Publications (1)

Publication Number Publication Date
PL3034073T3 true PL3034073T3 (pl) 2019-11-29

Family

ID=38458097

Family Applications (2)

Application Number Title Priority Date Filing Date
PL08748930.8T PL2146704T3 (pl) 2007-04-19 2008-04-16 Zastosowanie kompozycji zawierającej formoterol i dipropionian beklometazonu do leczenia zaostrzenia astmy
PL16152451T PL3034073T3 (pl) 2007-04-19 2008-04-16 Zastosowanie kompozycji zawierającej formoterol i dipropionian beklometazonu do zapobiegania i/lub leczenia zaostrzenia astmy

Family Applications Before (1)

Application Number Title Priority Date Filing Date
PL08748930.8T PL2146704T3 (pl) 2007-04-19 2008-04-16 Zastosowanie kompozycji zawierającej formoterol i dipropionian beklometazonu do leczenia zaostrzenia astmy

Country Status (30)

Country Link
US (1) US20080261932A1 (pl)
EP (3) EP1982709A1 (pl)
JP (2) JP5492072B2 (pl)
KR (3) KR101621676B1 (pl)
CN (1) CN101657191B (pl)
AU (1) AU2008241045C1 (pl)
BR (1) BRPI0809800A2 (pl)
CA (1) CA2684539A1 (pl)
CO (1) CO6220945A2 (pl)
CY (1) CY1117568T1 (pl)
DK (1) DK2146704T3 (pl)
EA (1) EA018589B1 (pl)
ES (2) ES2740103T3 (pl)
GE (1) GEP20145999B (pl)
HK (1) HK1137357A1 (pl)
HR (1) HRP20160588T1 (pl)
HU (1) HUE029263T2 (pl)
IL (1) IL201632A (pl)
MA (1) MA31315B1 (pl)
ME (1) ME00945B (pl)
MX (1) MX2009010851A (pl)
MY (1) MY169579A (pl)
NZ (1) NZ580526A (pl)
PL (2) PL2146704T3 (pl)
RS (1) RS54874B1 (pl)
SI (1) SI2146704T1 (pl)
TN (1) TN2009000390A1 (pl)
TR (1) TR201909857T4 (pl)
UA (1) UA100237C2 (pl)
WO (1) WO2008128685A1 (pl)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1982709A1 (en) * 2007-04-19 2008-10-22 CHIESI FARMACEUTICI S.p.A. Use of a composition comprising formoterol and beclomethasone dipropionate for the prevention or treatment of an acute condition of asthma
DK2727582T3 (en) * 2009-10-02 2016-05-17 Chiesi Farma Spa Pharmaceutical aerosol formulations of formoterol and beclomethasone dipropionate
CN102247597B (zh) * 2010-05-19 2015-01-07 天津金耀集团有限公司 一种糖皮质激素与支气管扩张剂的吸入剂
RS63706B1 (sr) * 2012-01-25 2022-11-30 Chiesi Farm Spa Formulacija suvog praha koja sadrži kortikosteroid i beta-adrenergik, za primenu inhalacijom
US11052202B2 (en) * 2012-11-07 2021-07-06 Chiesi Farmaceutici S.P.A. Drug delivery device for the treatment of patients with respiratory diseases
PH12019500577B1 (en) * 2016-09-19 2023-09-08 Mexichem Fluor Sa De Cv Pharmaceutical composition
CN107233311B (zh) * 2017-06-27 2020-12-04 长风药业股份有限公司 一种以阿福特罗和格隆溴铵为活性成分的雾化剂及其制备方法
US20210315842A1 (en) * 2018-06-04 2021-10-14 Lupin Inc. Stable pharmaceutical compositions for pressurized metered dose inhalers
WO2024097413A1 (en) * 2022-11-03 2024-05-10 Dana-Farber Cancer Institute, Inc. Methods of treating anemia using formoterol or a pharmaceutically acceptable salt thereof

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5795564A (en) * 1991-04-05 1998-08-18 Sepracor, Inc. Methods and compositions for treating pulmonary disorders using optically pure (R,R)-formoterol
HU227519B1 (en) 1991-12-18 2011-07-28 Astra Ab Synergic pharmaceutical composition containing combination of formoterol and budesonide
SE9802073D0 (sv) * 1998-06-11 1998-06-11 Astra Ab New use
AU2000250701B2 (en) 2000-05-22 2004-07-01 Chiesi Farmaceutici S.P.A. Stable pharmaceutical solution formulations for pressurised metered dose inhalers
FI20002177A0 (fi) * 2000-10-02 2000-10-02 Orion Yhtymae Oyj Uusi yhdistelmä astman hoitoon
FI20002215A0 (fi) * 2000-10-06 2000-10-06 Orion Yhtymae Oyj Yhdistelmäpartikkelit
FI20002216A0 (fi) 2000-10-06 2000-10-06 Orion Yhtymae Oyj Yhdistelmäpartikkelit astman hoitoon
SI1480615T1 (sl) 2002-03-01 2010-07-30 Chiesi Farma Spa Superfina formulacija formoterola
EP1982709A1 (en) * 2007-04-19 2008-10-22 CHIESI FARMACEUTICI S.p.A. Use of a composition comprising formoterol and beclomethasone dipropionate for the prevention or treatment of an acute condition of asthma

Also Published As

Publication number Publication date
BRPI0809800A2 (pt) 2014-10-07
AU2008241045B2 (en) 2013-06-20
CN101657191A (zh) 2010-02-24
IL201632A0 (en) 2010-05-31
US20080261932A1 (en) 2008-10-23
DK2146704T3 (en) 2016-05-23
UA100237C2 (uk) 2012-12-10
AU2008241045C1 (en) 2023-06-15
EP2146704A1 (en) 2010-01-27
EP3034073B1 (en) 2019-06-12
KR20100014408A (ko) 2010-02-10
KR101621676B1 (ko) 2016-05-16
EA200901201A1 (ru) 2010-04-30
KR20150082699A (ko) 2015-07-15
TR201909857T4 (tr) 2019-07-22
CN101657191B (zh) 2014-06-11
JP2014005312A (ja) 2014-01-16
JP5492072B2 (ja) 2014-05-14
MX2009010851A (es) 2009-11-05
AU2008241045A1 (en) 2008-10-30
MY169579A (en) 2019-04-22
RS54874B1 (sr) 2016-10-31
MA31315B1 (fr) 2010-04-01
CY1117568T1 (el) 2017-04-26
ES2740103T3 (es) 2020-02-05
CO6220945A2 (es) 2010-11-19
WO2008128685A1 (en) 2008-10-30
TN2009000390A1 (en) 2010-12-31
HRP20160588T1 (hr) 2016-07-01
EP2146704B1 (en) 2016-03-23
GEP20145999B (en) 2014-01-10
CA2684539A1 (en) 2008-10-30
ME00945B (me) 2012-06-20
JP2010524873A (ja) 2010-07-22
HK1137357A1 (en) 2010-07-30
EP3034073A1 (en) 2016-06-22
ES2568497T3 (es) 2016-04-29
EP1982709A1 (en) 2008-10-22
KR20150038618A (ko) 2015-04-08
EA018589B1 (ru) 2013-09-30
PL2146704T3 (pl) 2016-09-30
SI2146704T1 (sl) 2016-05-31
KR101668203B1 (ko) 2016-10-20
HUE029263T2 (en) 2017-02-28
NZ580526A (en) 2012-07-27
IL201632A (en) 2016-09-29

Similar Documents

Publication Publication Date Title
HRP20160588T1 (hr) Upotreba pripravka koji sadrži formoterol i beklometazon-dipropionat za liječenje pogoršane astme
HK1202558A1 (en) Compositions and methods for the therapy and diagnosis of influenza
PL1919450T3 (pl) Kompozycja liposomowa zawierająca lek przeciwhistaminowy i kortykosteroid oraz jej zastosowanie do wytwarzania leku do leczenia nieżytu nosa i chorób spokrewnionych
EP2022495A4 (en) COMPOSITION TO PREVENT THE IMPACT OF A CARDIOVASCULAR EVENT IN PATIENTS WITH MULTIPLE RISK
SI2118074T1 (sl) Spojine za preprečevanje in zdravljenje kardiovaskularnih bolezni
AP2965A (en) Therapeutic compositions and the use thereof
AP2490A (en) Therapeutic compositions and the use thereof
HK1144915A1 (en) Leishmania sterol 24-c-methyltransferase compositions for the prevention, treatment and diagnosis of leishmaniasis 24-c-
IL222542A (en) Use of a compound to prepare a drug to inhibit and diagnose proteinuria in the lung
EP1883416A4 (en) COMPOSITIONS AND METHODS FOR PREVENTING AND TREATING CONDITIONS RELATED TO INFLAMMATION
EP2007385A4 (en) CARDIOVASCULAR COMPOSITION AND ITS USE FOR THE TREATMENT OF MORBUS ALZHEIMER
IL205320A0 (en) Compositions comprising an electrochemically altered fluid and a therapeutic agent and use thereof for treating lung or respiratory diseases
IL196465A0 (en) Compositions and methods for the treatment of mucositis
IL196843A0 (en) Compositions and methods for the treatment of radiation proctosigmoitis
PL2121025T3 (pl) Sposoby i kompozycje dla dostarczania czynnika terapeutycznego
EP1982724A4 (en) THERAPEUTIC AGENT FOR THE TREATMENT OF METABOLIC SYNDROME AND FOODS CONTAINING THE SAME
EP2056857A4 (en) PHARMACEUTICAL COMPOSITIONS WITH CCL2 AND THEIR USE IN THE TREATMENT OF INFLAMMATION
IL193369A0 (en) A nebulizer formulation and kit containing formoterol and budesonide
EP2004216A4 (en) AGENT FOR THE TREATMENT OF HORMONO-DEPENDENT DISORDERS AND USES THEREOF
IL206657A0 (en) Substituted oxindole-derivatives and the use thereof for the treatment of vasopressin-dependent illnesses
EP2005964A4 (en) MEDICAMENT FOR TREATING HYPERPHOSPHATEEMIA AND PREPARATION METHOD THEREOF
EP2231146A4 (en) Pharmaceutical composition for the treatment and prevention of glaucoma
HK1167817A1 (en) Pharmaceutical aerosol formulations of formoterol and beclometasone dipropionate
TWI370735B (en) Use of agomelatine in obtaining medicaments intended for the treatment of smith-magenis syndrome
EP1843781A4 (en) COMPOSITION FOR THE PREVENTION, TREATMENT AND DIAGNOSIS OF INFLAMMATORY CHRONIC DISEASES OF AIRWAYS
点击 这是indexloc提供的php浏览器服务,不要输入任何密码和下载